Machina Capital S.A.S. Sells 195,860 Shares of Kenvue Inc. $KVUE

Machina Capital S.A.S. reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 77.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,142 shares of the company’s stock after selling 195,860 shares during the quarter. Machina Capital S.A.S.’s holdings in Kenvue were worth $991,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in KVUE. Callan Family Office LLC acquired a new position in Kenvue during the second quarter worth $835,000. Pentwater Capital Management LP purchased a new position in shares of Kenvue in the second quarter valued at $977,094,000. Nuance Investments LLC purchased a new position in shares of Kenvue in the second quarter valued at $27,681,000. Quantinno Capital Management LP grew its stake in Kenvue by 59.5% in the 1st quarter. Quantinno Capital Management LP now owns 1,345,956 shares of the company’s stock valued at $23,204,000 after acquiring an additional 502,024 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in Kenvue in the 2nd quarter valued at about $275,204,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. HSBC dropped their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research note on Monday, August 10th. UBS Group lifted their price objective on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. Finally, Barclays upped their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Ten analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.29.

Kenvue Price Performance

KVUE opened at $19.31 on Friday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm has a market cap of $37.09 billion, a P/E ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a 52 week low of $14.06 and a 52 week high of $20.13. The business’s fifty day simple moving average is $18.44 and its 200 day simple moving average is $18.27.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Friday, October 30th. The company reported $0.29 EPS for the quarter, hitting analysts’ consensus estimates of $0.29. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. During the same quarter last year, the business posted $0.28 EPS. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is currently 95.45%.

Kenvue Profile

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.